Genovis AB (publ.) (STO:GENO)

Market Cap	1.90B
Revenue (ttm)	123.87M
Net Income (ttm)	23.63M
Shares Out	65.47M
EPS (ttm)	0.36
PE Ratio	80.34
Forward PE	61.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,324
Average Volume	44,452
Open	29.00
Previous Close	29.00
Day's Range	27.95 - 29.30
52-Week Range	17.10 - 31.25
Beta	1.91
RSI	60.10
Earnings Date	Aug 12, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.